David H. Wesorick, MD; Vineet Chopra, MD, MSc
Disclosures: Dr. Chopra reports grants from the Agency for Healthcare Research and Quality. Dr. Wesorick has disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-1400.
In this study, patients admitted with recurrent CDI that were treated with FMT had significantly lower rates of BSI than patients treated with antibiotics. FMT patients also experienced significantly shorter lengths of stay and higher rates of CDI cure and survival at 90 days. These data suggest that FMT may be a superior treatment for recurrent CDI in this patient population.
However, the observational nature of the study and the significant differences between the 2 treatment groups make it impossible to draw firm conclusions. Randomized controlled trials will be required to accurately compare the outcomes of these treatment strategies in this patient population.
Rivaroxaban failed to show noninferiority to warfarin for thromboprophylaxis in high-risk APS but was associated with a nonsignificant increased risk for arterial thrombosis.
Reasons for rivaroxaban's higher rates of thrombosis are not clear but could be related to targeting a single coagulation factor (as opposed to several with warfarin) or treatment interruption by patients due to lack of monitoring compared with warfarin.
Editorialists note that these results are consistent with a prior noninferiority study of rivaroxaban vs. warfarin in high-risk APS and suggest that warfarin remains the anticoagulant of choice for this condition.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Wesorick DH, Chopra V. Annals for Hospitalists - 19 November 2019. Ann Intern Med. 2019;171:HO1. doi: https://doi.org/10.7326/AWHO201911190
Download citation file:
Published: Ann Intern Med. 2019;171(10):HO1.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use